HEDIS Measure

Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis (AAB)

By working together, we can improve health outcomes for your patients, our members. The Healthcare Effectiveness Data and Information Set (HEDIS) helps us measure many aspects of performance. This tip sheet provides key details of the HEDIS measure for avoidance of antibiotic treatment for acute bronchitis and acute bronchiolitis.

What is the measure?

This measure is the percentage of episodes (each time a patient is seen for an evaluation in the office/facility) for members three months old and older with a diagnosis of acute bronchitis/bronchiolitis that did **not** result in the member receiving an antibiotic prescription the day of the visit plus three days after the visit.

Why This Measure Is Important?

Research on antibiotics and acute bronchitis concludes that antibiotics reduce coughing slightly but may cause side effects and contribute to antibiotic resistance. At least 30% of antibiotic courses prescribed in an outpatient setting are not needed, meaning antibiotics did not improve the outcome. Most of these medically unnecessary antibiotics are for acute respiratory conditions, such as bronchitis, colds, and sore throats caused by viruses.

How to Improve Your Quality Score?

Each patient's evaluation and treatment are unique, and your clinical evaluation will determine if antibiotics are needed for each individual encounter.

- Recognize that antibiotics are needed for some patients with comorbid conditions and differential (competing) diagnosis, when these ICD-10 codes are submitted on the sameclaim as acute bronchitis and antibiotics are prescribed. Adding these diagnosis codeswill remove the patient from the HEDIS measure. When this occurs, your HEDIS resultswill not be negatively impacted.
- More common differential (competing) diagnoses are:
 - Acute pharyngitis
 - Acute or chronic tonsillitis
 - Hypertrophy of tonsils
 - Acute or chronic suppurative otitis media
 - Acute or chronic sinusitis
 - Pneumonia
- Comorbid conditions include:
 - COPD
 - Emphysema
 - Malignant neoplasms including skin
 - HIV

- Disease upper respiratory tract
- UTI
- Skin infections, cellulitis, impetigo
- Acute lymphangitis
- Acute vaginitis
- STI/STD
- Disorders of the immune system
- Sickle cell disease
- Cystic fibrosis



All summaries of the measures contained herein are reproduced with permission from HEDIS Volume 2: Technical Specifications for Health Plans by the National Committee for Quality Assurance (NCQA). HEDIS® is a registered trademark of the NCQA. Arkansas Blue Cross Blue Shield is an Independent Licensee of the Blue Cross and Blue Shield Association.